Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity

• Published in: Molecular cancer therapeutics Vol. 15; no. 6; pp. 1353 - 1363
• Main Authors: Udayakumar, Thirupandiyur S, Stoyanova, Radka, Shareef, Mohammed M, Mu, Zhaomei, Philip, Sakhi, Burnstein, Kerry L, Pollack, Alan
• Format: Journal Article
• Language: English
• Published: United States 01.06.2016
• Subjects: Activating Transcription Factor 3 - metabolism; Androgen Antagonists - administration & dosage; Androgen Antagonists - pharmacology; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Drug Synergism; Gene Expression Regulation, Neoplastic - drug effects; Humans; Male; Mice; Neoplasm Transplantation; Phospholipid Ethers - administration & dosage; Phospholipid Ethers - pharmacology; Promoter Regions, Genetic - drug effects; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Proto-Oncogene Proteins c-akt - metabolism; Receptors, Androgen - genetics; Receptors, Androgen - metabolism; Signal Transduction - drug effects; Up-Regulation; Xenograft Model Antitumor Assays

Edelfosine is a synthetic alkyl-lysophospholipid that possesses significant antitumor activity in several human tumor models. Here, we investigated the effects of edelfosine combined with androgen deprivation (AD) in LNCaP and VCaP human prostate cancer cells. This treatment regimen greatly decrease...